摘要
目的分析研究在耐多药肺结核患者的临床治疗中,卷曲霉素联合莫西沙星的应用价值。方法以2018年7月-2020年8月为研究样本选取时间段,使用简单随机抽样法从此时间段于淄博市淄川区医院进行治疗的耐多药肺结核患者中选取86例,并以随机抽签法分为参照组和研究组,参照组患者使用莫西沙星配合常规疗法进行治疗,研究组则在此基础上应用卷曲霉素进行联合治疗,对两组患者生活质量、血清炎性因子变化以及不良反应发生率、肺功能、证候积分、治疗相关指标项进行比较。结果治疗前,两组患者生活质量、血清炎性因子比较,差异无统计学意义(P>0.05);治疗后,两组患者生活质量上升而血清炎性因子减少,但研究组改善情况显著优于参照组,差异有统计学意义(P<0.05);研究组患者不良反应发生率低于参照组(P<0.05),差异有统计学意义;治疗后,研究组肺功能显著提高,证候积分下降明显,优于参照组(P<0.05);治疗相关指标项比较,研究组优于对照组(P<0.05)。结论在耐多药肺结核患者的治疗中卷曲霉素联合莫西沙星具有较好的治疗效果,能够有效提升患者治疗效果、抑制炎性反应,且不会加重不良反应,治疗安全性高,在临床治疗中具有较高应用价值。
Objective To analyze clinical value of capreomycin combined with moxifloxacin in treatment of multi drug resistant pulmonary tuberculosis.Methods The paper chose 86 patients with MDR-TB treated in Zibo City Zichuan District Hospital from July 2018 to August 2020,and divided them into reference group and study group by simple random sampling method.Reference group was treated with moxifloxacin in combination with routine therapy,and study group with combined capreomycin therapy.Life quality,changes of serum inflammatory factors,incidence of adverse reactions,lung function,syndrome scores and treatment related indexes were compared between two groups.Results Before treatment,there was no significant difference in life quality and serum inflammatory factors between two groups(P>0.05).After treatment,life quality of two groups increased and serum inflammatory factors decreased,but improvement of study group was significantly better than reference group(P<0.05).Incidence of adverse reactions in study group was lower than reference group(P<0.05).Lung function and syndrome scores:after treatment,lung function of study group was significantly improved,syndrome scores decreased significantly,and index data were better than reference group(P<0.05);study group had more obvious advantages than reference group in treatment related index items and data(P<0.05).Conclusion In treatment of multi drug resistant pulmonary tuberculosis patients,aflatoxin combined with moxifloxacin can achieve high curative effect,can improve curative effect and inhibit inflammatory reaction of patients effectively,not aggravating adverse reaction,with high curative safety,which has high application value in clinical treatment.
作者
孙勇
SUN Yong(Zibo City Zichuan District Hospital,Zibo,Shandong,255100)
出处
《智慧健康》
2022年第27期79-83,共5页
Smart Healthcare
关键词
卷曲霉素
莫西沙星
耐多药肺结核
治疗价值
Capreomycin
Moxifloxacin
Multidrug resistant pulmonary tuberculosis
Curative value
